Enanta Pharmaceuticals, Inc. announced that its partner AbbVie received U.S. Food and Drug Administration (FDA) approval for an expanded indication for MAVYRET (glecaprevir/pibrentasvir). MAVYRET is an oral pangenotypic direct acting antiviral (DAA) therapy.
The expanded approval designates MAVYRET as the first and only eight-week treatment for adults and pediatric patients three years and older with acute Hepatitis C Virus (HCV). This broadens the patient population eligible for MAVYRET treatment.
This regulatory milestone is significant for Enanta as it derives royalty revenue from MAVYRET sales. The expanded indication has the potential to increase the market reach and commercial success of the drug, thereby positively impacting Enanta's royalty stream.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.